Navigation Links
VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia
Date:6/1/2011

LOS ANGELES and PERTH, Australia, June 1, 2011 /PRNewswire/ -- MMRGlobal, Inc. (OTCBB: MMRF) ("MMR") and VisiInc PLC (VZJ) (www.deutsch-boerse.com) have entered into an agreement to launch MMRGlobal's patented consumer and professional health IT products and services, including MMRPro for healthcare professionals (www.mmrprovideos.com) and the MyMedicalRecords Personal Health Record (PHR) (www.mmrvideos.com), on the Visi™ platform utilizing the Vistime product.  Vistime is a multi-file format, real-time 3D viewer for retrieval and viewing of large files, including medical imaging systems such as MRIs, scans and sonograms, over any Internet connection, including dial-up.  The system allows physicians and patients to view and discuss medical records including radiology images in an online meeting format, making MMR's MyMedicalRecords one of the world's most functional Personal Health Records systems that allows collaboration of multiple specialists in real time.

MMR will also integrate the Visi platform into its offerings on a global basis. The VisiInc technology will enable MMR users to render and distribute large multi-dimensional visual files within the MMR interface, including digital medical media such as MRI and CAD files at lightning-fast speed without any resolution degradation or enterprise infrastructure barrier regardless of Internet connection, including dial-up ("Vistime," www.vistime.com). 

With current and future planned products MMR and Visi see this as an opportunity in what is estimated to be a $2.4b market.

Jacques Blandin, Chief Executive Officer and Founder of VisiInc PLC, said, "Vistime is the world's easiest to use multi-file format, real-time 3D viewer for powerful collaboration of medical records, including radiological images, using Visi rapid visual rendering capabilities. Working with MMR, our plan is to offer a MyMedicalRecords Personal Health Record globally.  VisiInc will offer the product in Australia through its subsidiary Firmware Technologies. Integrating the Visi technology with the MMR PHR will allow consumers anywhere to simultaneously view and explore Personal Health Records including multi-dimensional data visualizations of any file type of any size, in real-time."

The Visi MMR relationship responds to that agenda and can represent the beginning of a next generation of Personal Health Management Systems for consumers and healthcare professionals," stated Robert H. Lorsch, Chairman and CEO of MMRGlobal, Inc.

About VisInc PLC

In May 2011 VisiInc PLC announced the completion of its merger with Firmware Technologies Inc and its subsequent quotation on the Frankfurt Stock Exchange. VisiInc.com

Through it's evolutionary Visi™ platform, VisiInc operates Vistime. Vistime is rapidly capturing global market share of major verticals such as Healthcare, Government, Engineering and Architecture, Mining, Oil & Gas, Exploration, Energy, Education, Advertising & Media and online Video Conferencing. Visi, the next evolution in visual communication, is capable of delivering solutions in both the physical and virtual environment in 3D. Vistime has been designed to integrate with the existing product offerings of the world's leading web collaboration and enterprise content management systems, enabling vendors to immediately expand their product capabilities and service offerings through Integrated Product Offerings, White Label and Private Label Offerings and OEM opportunities www.visiinc.com.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups.. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements  

Statements in this press release that are not strictly historical in nature, including future performance, expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements."  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMRGlobal, Inc.'s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, outcomes of the agreement between MMRGlobal, Inc. and VisiInc PLC, the risk its products and services are not adopted or viewed favorably by the healthcare community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; product integration in physician practices and hospitals; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company's marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the United States Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. 

ONLINE INFORMATION

http://www.visiinc.com
http://www.vistime.com

http://www.mmrglobal.com
http://www.mymedicalrecords.com
www.mmrprovideos.com
http://www.mmrtheater.com

VisiInc Contact:
Glenn Weiland, Vice President Global Communications VisiInc.com
m +61408909553
e   glenn.weiland@visiinc.com

MMRGlobal Contact:
Michael Selsman
Public Communications Co.
310-553-5732
ms@publiccommunications.biz


'/>"/>
SOURCE VisiInc PLC; MMRGlobal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Conn. , Feb. 22, 2017   Protein ... maker of Flublok® Influenza Vaccine , announced today ... Partnership for Influenza Vaccine Introduction (PIVI) and the Mongolian ... devastating impacts of the flu.  The doses of Flublok ... Mongolia for health care workers, ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 ... Market Research, titled, "Radiology Information System Market by Type, Component, ... Forecast, 2014-2022," the radiology information system market was valued at ... million by 2022, growing at a CAGR of 5.9% from ... over three-fifths share of the total market in 2015. ...
(Date:2/22/2017)... 22, 2017  Based on its recent analysis ... Sullivan recognizes SnooZeal, Inc. with the 2017 European ... innovative product that intelligently addresses the root causes ... through the clinically proven continuous transmucosal electrical stimulation ... is one of the most accessible anti-snoring products ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... The SeniorCare Investor will host an important webinar— Seniors ... 2017, at 1:00 PM ET. A recording of the webinar will also be made ... , If you want to find out what really happened in the seniors housing ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is a ... PTSD. , Established in 1977, our organization was at the forefront in working ... to civilian life were evident and served as the catalyst for the establishing ...
(Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased to ... Multi-Cook Oven offers up to four ovens in one. Control temperature, fan speed ... unmatched evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce this ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & Morton celebrated ... Oklahoma, on Feb. 21. , The celebration began with a ribbon cutting event ... the construction team and tribal leadership. , Choctaw Nation Durant Regional Medical ...
(Date:2/21/2017)... Angeles, CA (PRWEB) , ... February 21, 2017 , ... ... the United States according to the American Society of Plastic Surgeons. Some patients want ... address the functionality of their nose and improve their breathing ability. The team at ...
Breaking Medicine News(10 mins):